WHAT OTHERS SAY
"Professional societies and the advocacy community have been a fundamental component of AAADV from the beginning, creating a uniquely open environment for the discussion of problems and issues common to everyone with an interest in accelerating development of new, effective forms of cancer therapy."
Renzo Canetta, M.D.
Former Vice President, Global R&D Oncology Policy
Bristol-Myers Squibb Co.
Research and Development